2AB Stock Overview
A clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Barinthus Biotherapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.03 |
| 52 Week High | US$3.24 |
| 52 Week Low | US$0.74 |
| Beta | -0.72 |
| 1 Month Change | 14.44% |
| 3 Month Change | 0% |
| 1 Year Change | -64.24% |
| 3 Year Change | -88.02% |
| 5 Year Change | n/a |
| Change since IPO | -90.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2AB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 24.1% | -2.6% | -2.0% |
| 1Y | -64.2% | -13.2% | 6.8% |
Return vs Industry: 2AB underperformed the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 2AB underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 2AB volatility | |
|---|---|
| 2AB Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2AB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2AB's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 130 | Bill Enright | www.barinthusbio.com |
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company’s development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older.
Barinthus Biotherapeutics plc Fundamentals Summary
| 2AB fundamental statistics | |
|---|---|
| Market cap | €42.91m |
| Earnings (TTM) | -€55.57m |
| Revenue (TTM) | €14.38m |
3.1x
P/S Ratio-0.8x
P/E RatioIs 2AB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2AB income statement (TTM) | |
|---|---|
| Revenue | US$14.97m |
| Cost of Revenue | US$45.09m |
| Gross Profit | -US$30.12m |
| Other Expenses | US$27.71m |
| Earnings | -US$57.83m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.44 |
| Gross Margin | -201.19% |
| Net Profit Margin | -386.31% |
| Debt/Equity Ratio | 0% |
How did 2AB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 16:43 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Barinthus Biotherapeutics plc is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Yi Chen | H.C. Wainwright & Co. |
| Matthew Harrison | Morgan Stanley |